Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immunotherapy improves survival in some patients with metastatic triple negative breast cancer, according to late-breaking results from the IMpassion130 trial reported at the ESMO 2018 Congress in Munich.

22 Oct 2018

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

Results from a phase 3 clinical trial indicate that patients who have not benefited from standard therapy for ankylosing spondylitis, a chronic inflammatory disease characterized by back pain and sacroiliac-joint damage, may have another treatment option in the biologic drug ixekizumab.

22 Oct 2018

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced initial safety and preliminary anti-tumor activity from the FORWARD II expansion cohort assessing mirvetuximab soravtansine in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab).

22 Oct 2018

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Women with HER2-positive early breast cancer with small tumours have similar disease-free survival and lower risk of cardiac toxicity with a nine-week course of adjuvant trastuzumab compared to those treated for one year, according to a subgroup analysis of the Short-HER trial reported at ESMO 2018 Congress in Munich.

22 Oct 2018

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Normally, the blood protein fibrin does not enter the brain. But in several neurological disorders, the blood-brain barrier--which keeps large molecules in the blood from entering the brain--becomes abnormally permeable, allowing fibrin to leak into the brain and trigger inflammation.

16 Oct 2018

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

The National Institute of General Medical Sciences of NIH has awarded a Small Business Innovative Research grant to Allele Biotechnology and Pharmaceuticals to develop new single-domain nanoantibody therapies for the treatment of sepsis.

15 Oct 2018

Research holds promise for treatment of pediatric brain cancer

New research published in Nature Communications from scientists at Huntsman Cancer Institute at the University of Utah, in collaboration with the Stanford University School of Medicine, shows a specific protein regulates both the initiation of cancer spreading and the self-renewal of cancer cells in medulloblastoma, a type of pediatric brain cancer.

12 Oct 2018

A new vaccine shows promise in protecting people from rabies, Lassa fever

A novel vaccine designed to protect people from both Lassa fever and rabies showed promise in preclinical testing, according to new research published in Nature Communications.

12 Oct 2018

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

For the third time since 2013, the German Institute for Quality and Efficiency in Health Care (IQWiG) examined in an early benefit assessment the added benefit of the drug pertuzumab in the treatment of HER2-positive breast cancer.

12 Oct 2018

Cornell dots equipped with antibody fragments offer a new cancer weapon

Antibody-based imaging of a particularly aggressive form of breast cancer is undergoing clinical trials worldwide, but the path from trial to application is being hampered by a major obstacle: safety.

12 Oct 2018

New vaccine shows effective protection in animal models of Lassa fever

Lassa fever belongs to the same class of hemorrhagic fevers as Ebola. Like Ebola, it has been a major health threat in Western Africa, infecting 100,000-300,000 people and killing 5,000 per year.

11 Oct 2018

Researchers develop new techniques for faster detection of Lyme disease bacteria

Researchers have developed techniques to detect Lyme disease bacteria weeks sooner than current tests, allowing patients to start treatment earlier.

11 Oct 2018

Maternal Tdap immunization during third trimester linked with higher levels of pertussis antibodies in newborns

Risk of whooping cough (pertussis) is highest in infants too young to have completed their primary immunization series (6 months old or younger) and they are at highest risk of developing life-threatening complications.

10 Oct 2018

New hope for children with aggressive form of cancer

Children with an aggressive form of cancer are being given new hope in a world-first trans-Atlantic clinical trial that will test a new three-part treatment.

10 Oct 2018

Antibody Screening Tools; Improving Workflows

Antibody screening tools have exponentially increased the rate that candidates can be screened, multiplexing will increase processing to thousands per hour.¬

From Sartorius 9 Oct 2018

Arcus Biosciences announces presentation of final results from Phase 1 study of AB928 at ESMO 2018

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that it will present final results from the Phase 1 study of AB928, its dual adenosine receptor antagonist, in healthy volunteers during a poster display session at the European Society of Medical Oncology 2018 Congress, being held October 19-23, 2018, in Munich, Germany.

8 Oct 2018

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

Novartis today announced that both the US Food and Drug Administration and European Medicines Agency have accepted the company's New Drug Application and Marketing Authorization Application respectively, for investigational oral, once-daily siponimod (BAF312) for the treatment of secondary progressive multiple sclerosis in adults.

8 Oct 2018

UTMB researchers develop less expensive way to produce vaccines

Researchers at The University of Texas Medical Branch at Galveston have developed less expensive way to produce vaccines that cuts the costs of vaccine production and storage by up to 80 percent without decreasing safety or effectiveness.

6 Oct 2018

Researchers receive $1.2 million grant to test potential treatment for metastatic breast cancer

A team of Medical University of South Carolina Hollings Cancer Center researchers received a three-year, $1.2 million grant from the U.S. Department of Defens to test a potential therapeutic antibody that could block breast cancer growth with fewer side effects, opening up potential for future drug development.

5 Oct 2018

Antibody News and Research

Further Reading

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Immunotherapy increases survival in some patients with metastatic triple negative breast cancer

Immune therapy may be potential treatment option for patients with hard-to-treat ankylosing spondylitis

ImmunoGen announces study results of platinum-resistant ovarian cancer therapy at ESMO 2018 Congress

Shorter course of trastuzumab could be an option for women with HER2+ early breast cancer

Researchers develop fibrin-targeting immunotherapy to protect against neurodegeneration

Allele awarded NIH grant to develop nanoantibody therapies for treatment of sepsis

Research holds promise for treatment of pediatric brain cancer

A new vaccine shows promise in protecting people from rabies, Lassa fever

Study shows no added benefit of pertuzumab combination in treatment of early breast cancer

Cornell dots equipped with antibody fragments offer a new cancer weapon

New vaccine shows effective protection in animal models of Lassa fever

Researchers develop new techniques for faster detection of Lyme disease bacteria

Maternal Tdap immunization during third trimester linked with higher levels of pertussis antibodies in newborns

New hope for children with aggressive form of cancer

Antibody Screening Tools; Improving Workflows

Arcus Biosciences announces presentation of final results from Phase 1 study of AB928 at ESMO 2018

FDA and EMA accept Novartis' regulatory application for siponimod to treat SPMS in adults

UTMB researchers develop less expensive way to produce vaccines

Researchers receive $1.2 million grant to test potential treatment for metastatic breast cancer

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo